Danish Firm Nuevolution Lends Screening Technology to Epigenetics Therapeutics Project

Oct 06, 2010

NEW YORK (GenomeWeb News) – Danish drug discovery firm Nuevolution today said it will employ its screening technology as part of a consortium to identify and develop small molecule drugs against epigenetic disorders.

Nuevolution, based in Copenhagen, Denmark, joins the consortium that also includes EpiTherapeutics, ExpreS2ion Biotechnologies, and the research group of Kristian Helin at the Biotech Research & Innovation Centre at the University of Copenhagen.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Featured White Papers

Biomarker Data Management in Clinical Trials: Addressing the Challenges of the New Regulatory Landscape

Albumin Removal Reference Applications

Accelerated Precision Antibody Discovery - Why Scalable Cloud Data Platforms Are the Future of Biologic Drug Development

May

15

Featured Webinar

Reaping the Benefits of Algorithm-Driven Research in Synthetic Biology

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Main menu